Biopharma | April 28, 2026
Lilly buys Ajax Therapeutics for up to $2.3 billion to target rare blood cancers
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
_256_275.jpeg)
